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Erythroid Krüppel-like factor (EKLF) plays an important role in
erythroid development by stimulating β-globin gene expression.
We have examined the details by which the minimal transactiva-
tion domain (TAD) of EKLF (EKLFTAD) interacts with several tran-
scriptional regulatory factors. We report that EKLFTAD displays
homology to the p53TAD and, like the p53TAD, can be divided into
two functional subdomains (EKLFTAD1 and EKLFTAD2). Based on
sequence analysis, we found that EKLFTAD2 is conserved in KLF2,
KLF4, KLF5, and KLF15. In addition, we demonstrate that EKLFTAD2
binds the amino-terminal PH domain of the Tfb1/p62 subunit of
TFIIH (Tfb1PH/p62PH) and four domains of CREB-binding protein/
p300. The solution structure of the EKLFTAD2/Tfb1PH complex
indicates that EKLFTAD2 binds Tfb1PH in an extended conforma-
tion, which is in contrast to the α-helical conformation seen for
p53TAD2 in complex with Tfb1PH. These studies provide detailed
mechanistic information into EKLFTAD functions as well as insights
into potential interactions of the TADs of other KLF proteins. In
addition, they suggest that not only have acidic TADs evolved
so that they bind using different conformations on a common tar-
get, but that transitioning from a disordered to a more ordered
state is not a requirement for their ability to bindmultiple partners.
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The Krüppel-like factors (KLF) are regulatory proteins thatfunction in a number of tissue-specific processes (1, 2). All
KLF proteins contain a DNA-binding domain (DBD) consisting
of three zinc fingers positioned at their carboxyl-terminal end that
enables them to bind to “GT-box” or “CACCC” sites (1, 2). KLF
proteins vary considerably at their amino-terminal region, and
they can be divided into subgroups based on this region (1, 2).
The amino-terminal regions of several KLF proteins contain
transcriptional regulatory domains including acidic transactiva-
tion domains (TADs), Sin-3 interacting repressor domains, and
CtBP2 interacting repressor domains (PVLS/T motifs) (2).
Erythroid Krüppel-like factor (EKLF/KLF1) is an activator
that plays a key role in erythroid development (3, 4). EKLF
stimulates β-globin gene expression and helps enable the switch
from the fetal γ-globin to the adult β-globin (5–9). EKLF speci-
fically binds to CAACC elements (1, 3) and either the absence of
EKLF or mutations in the β-globin CAACC element leads to
severe β-thalassemia (5, 6, 10). In addition, EKLF plays a role
in generating an open chromatin structure on the adult β-globin
gene through interactions with transcriptional regulatory factors
(11–16).
The human EKLF protein has 362 amino acids and contains
two functional domains: the carboxyl-terminal DBD (residues
292–362) and an amino-terminal TAD (residues 1–271) (3, 17).
Like the DBD, the TAD plays an important role in EKLF’s ability
to activate β-globin expression (16–18). Initial experiments
demonstrated that the first 100 residues constituted the minimal
TAD of EKLF (EKLFTAD) (17). Subsequent experiments
demonstrated that the first 40 residues within EKLFTAD play
a role in recruiting cofactors required for β-globin activation
and that residues 50 to 90 are essential for β-globin gene activa-
tion (17). EKLFTAD is highly acidic, and the combination of
acidic and hydrophobic amino acids within this domain is similar
to that found in the TAD of other activators including the tumor
suppressor protein p53 and the herpes simplex viral protein 16
(VP16) (19, 20). The presence of two critical regions within
EKLFTAD is also consistent with the fact that the TAD of
both p53 and VP16 contain two subdomains each capable of
activating transcription (21, 22). In p53TAD, the two subdomains
(p53TAD1 and p53TAD2) participate in distinct interactions with
general transcription factors, the mediator complex, MDM2, and
the histone-acetyl transferase (HAT) CREB-binding protein
(CBP)/p300 (23–25).
Despite the importance of the EKLFTAD, mechanistic details
by which it interacts with other proteins to regulate EKLF func-
tion are limited. However, like other acidic TADs, it is thought
that EKLFTAD participates in interactions with transcriptional
regulatory factors such as general transcription factors, chroma-
tin remodeling complexes, and HATs (12–14, 16). In this article,
we demonstrate that EKLFTAD displays sequence homology to
the p53TAD and contains two functional subdomains (EKLF-
TAD1 and EKLFTAD2). Sequence comparisons indicate that
EKLFTAD2 is conserved in other KLF proteins and directly
binds the amino-terminal PH domain of the Tfb1/p62 subunit
of TFIIH (Tfb1PH/p62PH) and four domains of CBP/p300.
NMR structural analysis of an EKLFTAD2/Tfb1PH complex
demonstrates that EKLFTAD2 binds Tfb1PH in a unique man-
ner that is distinct from the TAD of either p53 or VP16 and that
Trp73 is a key residue at the interface (26, 27). Our studies sug-
gest that acidic TADs have evolved so that they are able to bind a
common target using different mechanisms and that coupled
folding and binding is not a strict requirement for acidic TADs
to bind to multiple partners.
Results
EKLFTAD Resembles the TAD of p53. Based on mutational analysis
and sequence comparison with p53 (Fig. 1), human EKLFTAD
can be divided in two subdomains EKLFTAD1 (residues 1–40)
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and EKLFTAD2 (residues 51–90) (17). To test if these subdo-
mains can function independently, we determined if they are cap-
able of activating transcription when tethered to a heterologous
DBD as previously observed for p53TAD1 (residues 1–40) and
p53TAD2 (residues 40–73). Similar to other studies in yeast (22),
p53TAD1 and p53TAD2 are both able to stimulate transcription
of a lacZ reporter gene when fused to the LexA-DBD, and the
two subdomains of p53TAD activate transcription at levels just
slightly lower (81% and 71%, respectively) than the positive con-
trol (Fig. S1). Likewise, EKLFTAD1 and EKLFTAD2 activate
transcription when fused to the LexA-DBD at levels 74% and
60% relative to the positive control (Fig. S1). These experiments
demonstrate that EKLFTAD1 and EKLFTAD2 are both able to
independently activate transcription in the yeast system when
tethered to the LexA-DBD.
EKLFTAD2 Is Conserved in Other KLF Proteins.The KLF family can be
divided into subgroups based on either phylogenetic analysis or
on the presence of specific domains at the amino-terminal end of
the protein (1, 2). In an attempt to identify other KLF members
with acidic TADs related to either EKLFTAD1 or EKLFTAD2,
we analyzed the amino acid sequences of all known human and
mouse KLF proteins. Our searches failed to identify KLF pro-
teins containing a region with significant homology to the region
of EKLFTAD1 that aligns with the region of p53TAD1 that forms
a helix when bound toMDM2 (23). However, we did identify four
KLF proteins (KLF2, KLF4, KLF5, and KLF15) containing a re-
gion with significant homology to the region of EKLFTAD2 that
resembles the region of p53TAD2 that forms a helix when bound
to Tfb1PH (Fig. 1) (27). This result is consistent with the fact that
EKLF, KLF2, KLF4, KLF5, and KLF15 are members of group 3
and group 4 of the human KLF proteins based on the phyloge-
netic analysis (1).
EKLFTAD2 Binds Tfb1PH/p62PH. Recent studies have demonstrated
that TFIIH is a rate-limiting factor during the elongation phase of
β-globin gene expression (28, 29), and this is consistent with the
fact that patients with mutations in TFIIH suffer from β-thalas-
semia (30). Together, these studies indicate that TFIIH plays a
crucial role in β-globin gene expression. Recently, we have shown
that the TADs of p53 and VP16 interact with the amino-terminal
PH domain of the Tfb1/p62 (Tfb1PH/p62PH) subunit of TFIIH
(26, 27). In the case of the p53, the interaction is specific for
p53TAD2 (27). Given the sequence homology between the TADs
of p53 and EKLF (Fig. 1), we examined whether or not EKLF-
TAD1 and EKLFTAD2 interact with Tfb1PH/p62PH. To quan-
titatively determine the apparent dissociation constants (Kd),
isothermal titration calorimetry (ITC) studies were performed.
The ITC experiments demonstrate that both p62PH and Tfb1PH
are able to bind EKLFTAD2 with similar Kd values (1.1 0.1 μM
and 1.0 0.2 μM, respectively) (Table 1). A weaker affinity is ob-
served for Tfb1PH with EKLFTAD1 (11 1 μM) by ITC. The
Kd values for EKLFTAD2 are comparable to those previously
determined for the interaction of p62PH and Tfb1PH with
p53TAD2 (3.2 0.6 μM and 0.39 0.07 μM, respectively) (27).
EKLDTAD2 and p53TAD2 Share a Common Binding Site.To help define
the binding site for EKLFTAD2 on both Tfb1PH and p62PH,
we performed NMR chemical shift titration studies. Additions
of unlabeled-EKLFTAD2 to either 15N-Tfb1PH or 15N-p62PH
resulted in significant changes in 1H and 15N chemical shifts for
several signals in both 1H-15N heteronuclear single quantum
coherence (HSQC) spectra (Fig. S2). When mapped onto the
structure of either Tfb1PH (Fig. 2A) or p62PH (Fig. 2B), the
residues exhibiting significant changes upon addition of EKLF-
TAD2 are located in strands β5, β6, β7 and the H1 helix. The che-
mical shift perturbations induced by EKLFTAD2 in both Tfb1PH
and p62PH are very similar to those observed for p53 binding to
Tfb1PH and p62PH (27). In addition, NMR displacement experi-
ments demonstrate that p53TAD2 and EKLFTAD2 compete for
a common binding site on Tfb1PH (Fig. 2 C and D).
EKLFTAD2 Binds to CBP/p300. The p53TAD also interacts with the
histone acetyltransferases CBP and p300 (CBP/p300) and acety-
lation of p53 by CBP/p300 is essential for p53-dependent activa-
tion (31, 32). Distinct interactions occur with both subdomains of
the p53TAD and p53TAD2 interacts with at least four domains
(TAZ1/CH1, KIX, the TAZ2/CH3, and IBID) of CBP/p300
(24, 25). Given the fact that EKLF has been shown to interact
with CBP/p300 and acetylation of EKLF by CBP is crucial for
activation of ß-globin gene expression (12–14), we tested if
EKLFTAD2 also binds to the same four domains of CBP/p300 as
p53TAD2 (24, 25). As with p53TAD2 (24, 25), ITC studies show
that all four domains of CBP/p300 bind to EKLFTAD2 with Kd
values ranging between 0.74 0.08 μM (TAZ2 domain) and
4.2 2.0 μM (IBiD domain) (Table 1).
Structure Determination of the Tfb1PH/EKLFTAD2 Complex. Next, we
pursued NMR structural studies of a complex containing Tfb1PH
and EKLFTAD2. Tfb1PH (yeast) was chosen as a model system
for NMR studies, because it is more stable then the homologous
p62PH (human) in solution. The three-dimensional structures
of the Tfb1PH/EKLFTAD2 complex were calculated using
1686 NOE-derived distance restraints, 47 intermolecular NOEs
(Table S1), 36 hydrogen-bond restraints, and 116 dihedral angle
restraints. The structure of the Tfb1PH/EKLFTAD2 complex is
well defined by the NMR data. The 20 lowest-energy structures
Fig. 1. EKLFTAD1 and EKLFTAD2 are homologous to p53TAD1 and
p53TAD2. (Top) Sequence alignments of EKLFTAD1 and EKLFTAD2 from
human EKLF with p53TAD1 and p53TAD2 from human p53. The residues
of p53 that form helices in the p53TAD1/MDM2 complex (23) and the
p53TAD2/Tfb1PH complex (27) are underlined in black. The hydrophobic
residues at the binding interfaces of the p53TAD1/MDM2 complex and the
p53TAD2/Tfb1PH are in gray. Several known or potential phosphorylation
sites are in bold. (Lower) Sequence alignment of regions of other KLF
proteins (mouse and human) that share homology with EKLFTAD2. The
KLF proteins are members of either KLF group 3 (EKLF, KLF2, KLF4) or KLF
group 4 (KLF5, KLF15) based on phylogenetic analysis (1). Key hydrophobic
residues are shaded gray and potential phosphorylation sites are in bold.
Table 1. Kd (μM) values determined by ITC
Kd, μM
Tfb1PH EKLFTAD2 1.0 ± 0.2
p62PH EKLFTAD2 1.1 ± 0.1
CBP KIX EKLFTAD2 1.2 ± 0.7
CBP IBiD EKLFTAD2 4.2 ± 2.0
CBP TAZ1 EKLFTAD2 3.0 ± 1.0
CBP TAZ2 EKLFTAD2 0.74 ± 0.08
p62PH EKLF TAD2 W73P n.b.
CBP IBiD EKLF TAD2 W73P n.b.
n.b., no binding detected.








(Fig. 3A) are characterized by good backbone geometry, no
significant restraint violation, and low pairwise rmsd values
(Table S2).
The structure of Tfb1PH in complex with EKLFTAD2 is com-
parable to that of free Tfb1PH (33), indicating that Tfb1PH does
not undergo significant structural changes between the free and
complex form (Fig. 3 A and B). Tfb1PH consists of two perpen-
dicular antiparallel-β sheets arranged in a β-sandwich (β1–β7) and
flanked on one side by a long α-helix (H1). EKLFTAD2 binds
Tfb1PH in an elongated conformation devoid of any regular sec-
ondary structural elements (Fig. 3 A and B). β-strands β5–β7 and
the H1 α-helix of Tfb1PH form an extensive interface with resi-
dues between Ala69 and Thr80 of EKLFTAD2 (Fig. 3 C and D),
and this is consistent with chemical shift changes of 15N-EKLF-
TAD2 upon addition of Tfb1PH (Fig. S2).
Tfb1PH/EKLFTAD2 Interface. EKLFTAD2 binds to a contiguous
shallow groove formed by β-strands β5, β6, and β7 and the H1
helix of Tfb1PH. The shallow groove of Tfb1PH is surrounded
by positively charged residues (Lys47, Lys57, Arg61, Arg86,
Lys97, Lys101, and Lys112) that position the negatively charged
EKLFTAD2 (Fig. S3) so that it can participate in a series of van
deer Waals contacts with hydrophobic pockets dispersed along
the entire length of the groove (Fig. 3C). Numerous contacts
are formed between Tfb1PH and Ala69, Ala71, Thr72, Trp73,
Leu75, Leu77, Leu79, and Thr80 of EKLFTAD2 (Fig. 3 C
and D). The key residue of EKLFTAD2 along the interface with
Tfb1PH appears to be Trp73, which inserts into a pocket formed
by Gln49, Ala50, Thr51, Met59, Leu60, Arg61, and Met88 of
Tfb1PH. This pocket is centrally located within the groove,
and in this pocket Trp73 forms a cation-π interaction with
Arg61 and an amino-π interaction with Gln49 (Fig. 3D). Other
important van der Waals contacts are generated by Ala71 of
EKLFTAD2 inserting into a cleft formed by residues in strand
β5 (Thr51), strand β6 (Met59), and the loop between strands
β5 and β6 (Pro52 and Lys57) of Tfb1PH at one end of the groove
and Leu79 of EKLFTAD2 inserting into a pocket formed by re-
sidues in strand β5 (Leu48) and in helix H1 (Gln105, Ile108, and
Ser109) of Tfb1PH at the other end. In addition to the interac-
tions involving hydrophobic residues, there are two potential salt
bridges between acidic residues of EKLFTAD2 and Tfb1PH
(Fig. S3). One is formed between Asp76 of EKLFTAD2 and
Lys101 of Tfb1PH, and the second one is formed between
Asp70 of EKLFTAD2 and Lys57 of Tfb1PH.
Fig. 2. EKLFTAD2 and p53TAD2 share a common
binding site on Tfb1PH/p62PH. Ribbon models of
the 3D structures of Tfb1PH (A) and p62PH
(B). The amino acids showing a significant chemical
shift change ðΔδðppmÞ > 0.15;Δδ ¼ ½ð0.17ΔNHÞ2þ
ðΔHNÞ21∕2Þ upon formation of a complex with EKLF-
TAD2 are shown in yellow (A and B). (C) Overlay of a
selected region from the two-dimensional 1H-15N
HSQC spectra for a 0.5-mM sample of 15N-labeled
p53TAD2 in the free form (black) and in the presence
of 0.4 mM unlabeled Tfb1PH (pink). (D) Overlay of a
selected region from the two-dimensional 1H-15N
HSQC spectra for a 0.5-mM sample of 15N-labeled
p53TAD2 in the free form (black), in the presence
of 0.4 mM unlabeled Tfb1PH (pink), and after addi-
tion of 0.5 mM unlabeled EKLFTAD2 (aqua). Signals
that undergo significant changes in 1H and 15N che-
mical shifts upon formation of the complex with
Tfb1PH (C) and that return toward their original
position following the addition of EKLFTAD2
(D) are indicated by arrows.
Fig. 3. Structure of the Tfb1PH/EKLFTAD2 Complex. (A) Overlay of the 20
lowest-energy structures of the complex between Tfb1PH (blue) and EKLF-
TAD2 (yellow). The structures were superimposed using the backbone atoms
C′, Cα, and N of residues 4–65 and 85–112 of Tfb1PH and residues 59–84 of
EKLFTAD2. (B) Ribbon model of the lowest-energy conformer of the complex
between Tfb1PH (blue) and EKLFTAD2 (yellow). (C) Three-dimensional struc-
ture of Tfb1PH is shown as molecular surface (blue), and EKLFTAD2 is repre-
sented as a tube (yellow). The side chains of several hydrophobic residues of
EKLFTAD2 (Trp73, Leu75, Leu77, and Leu79) that form the interface with
Tfb1PH are shown as sticks. (D) Three-dimensional structure of Tfb1PH is
shown as ribbon (blue), and EKLFTAD2 is represented as a tube (yellow).
The side chain of Trp73 (EKLFTAD2) is positioned in a pocket formed by
Gln49, Arg61, and M88 of Tfb1.
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Trp73 Is Crucial for EKLFTAD Functions. To examine the func-
tional role of Trp73 of EKLF, we generated a proline mutant
(W73P) and tested EKLF function in an in vivo β-globin acti-
vation assay. Because EKLF contains a second activation
domain (residues 140–232 in hEKLF) that is also sufficient for β-
globin gene expression (34, 35), the mutation was tested in an
EKLF construct deleted for the redundant activation domain
(EKLFW73PΔ140–232). In this assay, EKLFΔ140–232 activates β-glo-
bin expression in K562 erythroid cells to similar levels as full-
length EKLF as expected. In contrast, the EKLFW73PΔ140–232
mutant shows significantly lower activity (approximately 5-fold)
(Fig. 4), indicating that Trp73 is important for the β-globin acti-
vation associated with the minimal activation domain of EKLF
(EKLFTAD). Likewise, a W73P mutant generated in the context
of a 104 amino acid mEKLF TAD segment fused to the GAL4
DBD significantly reduces its ability to activate a GAL4-TK-β-
globin-reporter gene in K562 cells (17) (Fig. S4). These in vivo
results are also consistent with ITC studies demonstrating that
an EKLFTAD2 (W73P) mutant is unable to bind to either
p62PH or the IBiD domain of CBP/p300 (Table 1). Together,
these results indicate that Trp73 of EKLF forms important inter-
actions with CBP/p300 and TFIIH that may be required for
EKLF functions in vivo.
Discussion
The structures of EKLFTAD2, p53TAD2 (27), and VP16C (26)
bound to Tfb1PH allow us to make comparisons between the
three acidic TADs bound to a common target. In both the
p53TAD2/TFb1PH and the VP16C/Tfb1PH complexes (26, 27),
three hydrophobic residues on one face of the α-helix make cru-
cial contacts with Tfb1PH and in both cases one of the hydropho-
bic residues (Phe54 of p53TAD2 and Phe479 of VP16C) is
inserted into the same pocket on Tfb1PH as Trp73 of EKLF-
TAD2 (Fig. S5 A and B). In this pocket, the phenylalanine resi-
dues of p53TAD2 and VP16C participate in virtually identical
interactions with Tfb1PH as observed for Trp73 in EKLFTAD2.
Surprisingly, this is the only real similarity between the EKLF-
TAD2/Tfb1PH complex and either the p53TAD2/Tfb1PH or
VP16C/Tfb1PH complex along the binding interface. However,
by binding in an elongated form, EKLFTAD2 contributes a sig-
nificantly larger interface (≈700 Å2) than either p53TAD2
(≈380 Å2) or VP16C (≈500 Å2) in complex with Tfb1PH.
Previous structural studies indicate that acidic TADs have
the capability to interact with multiple partners due to their abil-
ity to couple folding with binding (23, 36–38). The transition of
p53TAD2 and VP16C from a disordered state to a helical con-
formation when bound to Tfb1PH is consistent with this idea
(26, 27). In contrast, EKLFTAD2 binds to Tfb1PH in a nonhe-
lical form, and this indicates that acidic TADs can recognize iden-
tical target proteins using different structural conformations. The
structures of p53TAD2, VP16C, and EKLFTAD2 in complex
with Tfb1PH/p62PH also suggest that coupling folding and bind-
ing is common, but not a strict requirement for TADs interacting
with their partner proteins. This is further supported by the struc-
ture of a complex containing the acidic carboxyl-terminal domain
of the alpha subunit of the general transcription factor IIE
(TFIIEαCTD) bound to p62PH. In this structure, an acidic re-
gion of TFIIEαCTD binds in a virtually identical conformation
as EKLFTAD2 along the same binding interface and inserts a
phenylalanine side chain (Phe387) in the same pocket of Tfb1PH
as Trp73 (Figs. S5C and Fig. S6) (39, 40).
A similar situation is observed with the structures of the TADs
of STAT2, CITED2, and HIF-1α bound to the TAZ1 domain of
CBP (36, 38, 41). These TADs bind to the same surface of TAZ1,
but they bind using two different orientations (N to C and C to N)
and by utilizing different combinations of helical segments.
Despite binding through distinct mechanisms they differ from
EKLFTAD2 in that all three of these acidic TADs require the
formation of an alpha helical conformation through a coupled
folding and binding mechanism (36, 38, 41). However, they
clearly demonstrate that the target (TAZ1) is able to bind acidic
TADs containing different structural conformations.
The interaction of EKLFTAD with Tfb1PH/p62PH is consis-
tent with the fact that TFIIH is required for β-globin expression
and a mutation in TFIIH leads to β-thalassemia (28–30). The
structure of the Tfb1PH/EKLFTAD2 complex demonstrates that
Trp73 is crucial for this interaction and is supported by in vivo
results demonstrating that mutations of Trp73 leads to signifi-
cantly lower levels of β-globin gene activation in K562 cells.
The results demonstrating that EKLFTAD2 binds the same four
subdomains of CBP as p53TAD2 are in agreement with studies
demonstrating that acetylation of EKLF by CBP is required for
activation of β-globin gene expression (12–14). As was the case
for binding to Tfb1PH/p62PH, Trp73 is important for EKLF-
TAD2 interaction with CBP. These results also suggest that
p53TAD2 and EKLFTAD2 may share other common binding
partners, but they may bind these targets using different confor-
mations.
Sequence comparisons indicate that a domain similar to
EKLFTAD2 is also present in KLF2, KLF4, KLF5, and KLF15
(Fig. 1) (1). This is supported by studies demonstrating that these
four KLF proteins all interact with CBP/p300 through the region
that is homologous to EKLFTAD2 (42–45). This strongly sug-
gests that KLF2, KLF4, KLF5, and KLF15 will bind to a number
of the same regulatory factors as EKLFTAD2. Additional struc-
tural and functional studies are needed to determine whether
these homologous regions of the other KLF proteins bind to their
target proteins in an elongated form like EKLFTAD2 or if they
form helices as typically seen with acidic TADs such as p53 and
VP16. In addition to the minimal EKLFTAD, EKLF contains
a second domain (residues 140–232) that is sufficient for activa-
tion of β-globin gene expression (34, 35). Mutational analysis
demonstrated that these domains appear to serve redundant
functions (34), although the mechanistic details by which this
second region of EKLF functions is not understood (35). The
primary sequences of the two domains are very different, with
EKLFTAD being very acidic (pI ¼ 3.8) and the region between
residues 140 and 232 being very basic (pI ¼ 9.7) with only two
acidic residues. However, the redundant functions suggest the
Fig. 4. Trp73 influences in vivo activation of β-globin gene expression. K562
cells were cotransfected with plasmids expressing the luciferase reporter
gene under control of ß-globin promoter along with the EKLF constructs
(EKLF, EKLFΔ140–232, and EKLFW73PΔ140–232). A plasmid expressing Renilla lu-
ciferase was included as a control for normalization of transfection efficiency.
Transcriptional activities were normalized to that of full-length hEKLF, which
was set at 100%. Error bars represent standard error of the mean of three
independent experiments, each performed in triplicate. (Inset) The level of
expression of the proteins after transfection into Cos7 cells as monitored
by Western blot with an antibody against EKLF. Actin levels are shown as
a loading control.








two domains recruit the same transcriptional regulatory factors
and future studies are needed to determine if this second domain
of EKLF also binds TFIIH and CBP/p300.
Experimental Procedures
Cloning and Purification of Recombinant Proteins. EKLFTAD1
(residues 1–40) and EKLFTAD2 (residues 51–90) were cloned
into the pGEX-2T vector generating GST-fusion proteins starting
with the human EKLF cDNA. The KIX domain (residues
586–672) of human CBP was provided by Alanna Schepartz (Yale
University, New Haven, CT). The IBiD domain (residues 2065–
2115) of CBP was cloned in the pGEX-2T vector generating GST-
fusion protein starting with the human CBP cDNA. The TAZ1
domain (residues 345–439) of CBP was provided by Timothy
Osborne (University of California, Irvine, CA). The TAZ2 do-
main (residues 1723–1812)/C1738A, C1746A, C1789A, C1790A)
of p300 was provided by Ettore Appella (National Institutes of
Health, Bethesda, MD). The GST-Tfb1PH (residues 1–115) and
GST-p62PH (residues 1–108) were cloned as previously described
(33). QuickChange II site-directed mutagenesis kit (Startagene)
was used to carry out site-directed mutagenesis. For details of
protein purifications, see SI Experimental Procedures.
Isothermal Titration Calorimetry Binding Experiments. ITC titrations
were performed at 25 °C as previously described (27). Proteins
were dialyzed into 20 mM Tris buffer pH 7.5 except for KIX,
TAZ1, and TAZ2, which were dialyzed into 20 mM sodium phos-
phate buffer pH 6.4. The protein concentrations were determined
from A280. All injections fit a single-binding site mechanism with
1∶1 stoichiometry.
NMR Spectroscopy. For details of NMR samples, see SI
Experimental Procedures. NMR spectra were collected at 300 K
on Varian Unity Inova 500-, 600-, and 800-MHz spectrometers.
Interproton distance restraints were derived from 3D 15N-edited
NOESY-HSQC and 13C-edited HMQC-NOESY spectra (τm ¼
90 ms). Intermolecular distance restraints were obtained from
3D 15N∕13C fF1g-filtered, fF3g-edited NOESY experiments
(τm ¼ 90 ms). Hydrogen-bond restraints were derived from
slowly exchanging amide protons determined in H/D exchange
studies.
Structures Calculation. The NOE-derived distance restraints
were defined as strong (1.8–2.8 Å), medium (1.8–3.4 Å), weak
(1.8–5.0 Å), and very weak (3.3–6.0 Å). Backbone dihedral angles
were derived with the program TALOS (46). The EKLFTAD2/
Tfb1PH structures were calculated using the program CNS (47).
The figures were generated with PyMol (http://www.pymol.org).
Transactivation Assays in K562 Blood Cells. The EKLFΔ140–232 and
EKLFW73PΔ140–232 constructs were prepared from full-length
hEKLF. K562 cells were cotransfected with plasmids expressing
the luciferase reporter gene under control of the ß-globin promo-
ter along with the EKLF constructs as described previously
(17, 48). Expression levels of the proteins were determined with
an antibody directed against EKLF.
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SI Text
SI Experimental Procedures. Protein Expression and Purification. The
carboxyl-terminal domain of the alpha subunit of the general
transcription factor IIE (TFIIαCTD), the Pleckstin homology
domain of Tfb1 (Tfb1PH), and the Pleckstrin homology domain
of p62 (p62PH) were purified as previously described (1). The
minimal transactivation domain of EKLF (EKLFTAD), EKLF-
TAD1, EKLFTAD2 and CREB-binding protein (CBP)/p300
IBiD domain were expressed as GST-fusion proteins in Escheri-
chia coli host strain TOPP2 (EKLFTAD1, EKLFTAD2, IBiD
domain) or E. coli host strain Rosetta2 (EKLFTAD) and bound
to glutathione resin. The resin-bound proteins were incubated 2 h
with 100 units of thrombin (Calbiochem). Following the cleavage
reaction, the proteins were dialyzed overnight into 5% aqueous
acetic acid and further purified by reverse-phase HPLC over a C4
column (Vydac). The his-tagged KIX domain of CBP was first
bound with chelating sepharose FF resin (GE Healthcare)
charged with nickel, and the CBP-KIX protein was eluted with
imidazole buffer [20 mM phosphate buffer-HCl (pH 7.4),
500 mM imidazol, 0.5 M NaCl]. The eluted protein was dialyzed
overnight into 10% aqueous acetic acid and further purified by
reverse-phase HPLC over a C4 column (Vydac).
The TAZ1 and TAZ2 domains of CBP were expressed in
E. coli host strain BL21(DE3). The cells were grown at 37 °C,
and protein expression was induced for 4 h with 0.7 mM IPTG
at 37 °C. Cells were harvested, resuspended in buffer A [26 mM
Tris buffer pH 7.4, 1 mM DTT], lysed by passage through a
French press, and centrifuged at 15;000 × g for 20 min. The pel-
lets from the centrifugation were then resuspended in buffer A
with 6 M guanidinium HCl and centrifuged at 100;000 × g for
30 min. The supernatants were then dialyzed overnight into
5% aqueous acetic acid containing 2 mM DTT. The proteins
were further purified by reverse-phase HPLC over a C4 column
(Vydac). For NMR studies, uniformly (>98%) 15N-labeled and
15N∕13C-labeled proteins were prepared in minimal media.
GAL4 Transactivation Assays in Yeast.Transactivation assays in yeast
were performed as previously described (1). The results are pre-
sented as the mean of the percentage of the ß-galactosidase units
of the tested LexA-fusion proteins on the ß-galactosidase units of
the LexA-GAL4 positive control ± standard of the mean.
Western-blot analyses were performed with an antibody directed
at the LexA protein (Santa Cruz, sc-7544; 1∶1;000 dilution) to
verify equivalent expression of the LexA-fusion proteins.
NMR Samples. For structural studies of the Tfb1PH/EKLFTAD2
complex, the samples contained 1 mM 15N- or 15N∕13C-labeled
Tfb1PH and EKLFTAD2 was added to a final ratio of 1∶2. These
studies were performed in 20 mM sodium phosphate buffer
pH 6.5, 1 mM EDTA, 1 mM DTT (NMR buffer) with either
90%H2O∕10%D2O or 99.9%D2O. For the labeled EKLF experi-
ments, the samples contained 0.6 mM 15N- or 15N∕13C-labeled
EKLFTAD2, and Tfb1PH was added to a final ratio of 1∶2 in
NMR buffer.
For the NMR chemical shift titration studies of EKLFTADs
with Tfb1PH, either unlabeled EKLFTAD1 or unlabeled EKLF-
TAD2 was added to a sample containing 0.5 mM of 15N-Tfb1PH
in NMR buffer to a final ratio of 2∶1. For the NMR chemical shift
titration studies of EKLFTAD2 on p62PH, unlabeled EKLF-
TAD2 was added to a final ratio of 1∶1.5 to a sample containing
0.4 mM of 15N-p62PH in NMR buffer.
For the NMR competition experiment, a sample containing
0.5 mM 15N-labeled p53TAD2 (residues 40–73) in NMR buffer
was used. To this sample, unlabeled Tfb1PH was added to a final
concentration of 0.4 mM. In a second addition, unlabeled EKLF-
TAD2 was added to a final concentration of 0.5 mM.
GAL4 Transactivation Assays in K562 Blood Cells. Luciferase assays in
K562 blood cells were performed as described previously (2, 3).
The minimal EKLFTAD (residues 2–106 of mouse EKLF) was
fused to the DNA-binding domain of GAL4 (4) to create the
GAL4-fusion proteins. The W73 are based on the numbering
of the equivalent tryptophan residue in humans. Western-blot
analysis with an antibody directed at the GAL4 protein is used
to verify expression levels of the GAL-4 fusion protein.
1. Di Lello P, et al. (2008) p53 and TFIIEalpha share a common binding site on the
Tfb1/p62 subunit of TFIIH. Proc Natl Acad Sci USA 105:106–111.
2. Sengupta T, Cohet N, Morle F, Bieker JJ (2009) Distinct modes of gene regulation by a
cell-specific transcriptional activator. Proc Natl Acad Sci USA 106:4213–4218.
3. Chen XY, Bieker JJ (2004) Stage-specific repression by the EKLF transcriptional
activator. Mol Cell Biol 24:10416–10424.
4. Chen X, Bieker JJ (1996) Erythroid Krueppel-like factor (EKLF) contains a multifunc-
tional transcriptional activation domain important for inter- and intramolecular inter-
actions. EMBO J 15:5888–5896.
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LexA fusion protein % -Galactosidase units
LexA-EKLFTAD1 74.3 ± 8.7
LexA-EKLFTAD2 60.0 ± 7.0
LexA-p53TAD1 81.3 ± 9.0
LexA-p53TAD2 71.3 ± 3.5
LexA-GAL4TAD 100 ± 2
LexA 2 ± 1
Fig. S1. EKLFTAD1 and EKLFTAD2 function as independent activation domains in yeast. LexA-EKLF and LexA-p53 constructs were cotransformed into yeast
with the reporter LexA operator-Lac-Z fusion plasmid pSH18-34. Results are presented as themean of the percentages of the ß-galactosidase units of the tested
fusion proteins on the ß-galactosidase units of the LexA-GAL4TAD positive control. Error bars represent standard error about the mean of three independent
experiments.
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Fig. S2. EKLFTAD2 binds to Tfb1PH. (A) Overlay of the two-dimensional 1H-15N heteronuclear single quantum coherence (HSQC) spectra for 15N-labeled
Tfb1PH in its free from (dark blue), in the presence of 0.5 equivalents (pink), 1 equivalent (green), and 2 equivalents (light blue) of EKLFTAD2. (B) Histogram
of chemical shift variations ðΔδðppmÞ ¼ ½ð0.17ΔNHÞ2 þ ðΔHNÞ21∕2 from titration in A. (C) Overlay of the 2D 1H-15N HSQC spectra for 15N-labeled EKLFTAD2 in its
free from (black), in the presence of 0. 5 equivalent (pink), and 1.5 equivalent (light blue) of Tfb1PH. Arrows highlight several signals that undergo significant
changes in 1H and 15N chemical shifts in EKLFTAD2 upon formation of the TFb1PH/EKLFTAD2 complex. (D) Histogram of chemical shift variations
(ΔδðppmÞ ¼ ½ð0.17ΔNHÞ2 þ ðΔHNÞ21∕2 from titration in C.
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Fig. S3. Electrostatic interactions in the Tfb1PH/EKLFTAD2 complex. Three-dimensional structure of Tfb1PH shown as a molecular surface in which the
electrostatic potential is mapped between −10 kT (red) and þ10 kT (blue) either in the presence (A and C) or absence of EKLFTAD2 (B). In A, the 3D structure
of EKLFTAD2 is shown as mesh molecular surface with the same electrostatic potential mapped on the surface. In C, the two salt bridges that appear to
contribute to the stability of the Tfb1PH/EKLFTAD2 complex are highlighted. One salt bridge involves Asp70 of EKLFTAD2 and Lys57 of Tfb1PH. The second
salt bridge is between Asp76 of EKLFTAD2 and Lys101 of Tfb1PH. Asp70 and Asp76 of EKLFTAD2 are highlighted with red mesh and the backbone trace of
EKLFTAD2 and the side chain of Trp73 are shown in yellow.
Fig. S4. Trp73 is crucial for the binding and in vivo activity of the minimal EKLFTAD. K562 cells were cotransfected with the 5xGAL-TK-β-reporter gene
together with plasmids expressing the indicated GAL4-fusion proteins (4). A plasmid expressing Renilla luciferase was included as a control for normalization
of transfection efficiency. The transcriptional activity of these proteins was normalized. Error bars represent standard error about the mean of multiple
independent experiments. (Inset) The level of expression of the GAL4-fusion proteins as monitored by Western blot with an antibody against GAL4.
Hsp90 levels are shown as a loading control.
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Fig. S5. EKLFTAD2 and TFIIEα bind similarly to Tfb1PH/p62PH, but different from p53TAD2 and VP16C. (A) Overlay of EKLFTAD2 (yellow) and p53TAD2 (pink)
shown as tubes on the surface of Tfb1PH (blue). EKLTAD2 is in an extended conformation and p53TAD2 forms a 9-residue α-helix. In the overlay, the side chains
of Trp73 of EKLFTAD2 and Phe54 of p53TAD2 are located in the same pocket on Tfb1PH. (B) Overlay of EKLFTAD2 (yellow) and VP16 (orange) represented as
tubes in complex with Tfb1PH (blue). EKLTAD2 is in an elongated form and VP16 forms a 9-residue α-helix and the side chains of Trp73 of EKLFTAD2 and Phe479
of VP16C are located in the same binding pocket on Tfb1PH. (C) Overlay of TFIIEαCTD and EKLFTAD2 on the 3D structure of Tfb1PH. EKLFTAD2 (yellow) and
TFIIEαCTD (red) are represented as tubes on the surface of Tfb1PH (blue). In this overlay the side chains of Trp73 of EKLFTAD2 and Phe387 of TFIIEαCTD are
highlighted to show that they are located in the same binding pocket on Tfb1PH/p62PH.
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Fig. S6. EKLFTAD2 and TFIIEα bind similarly to Tfb1PH/p62PH. Overlay of TFIIEαCTD and EKLFTAD2 on the 3D structure of p62PH. EKLFTAD2 (yellow) and
TFIIEαCTD (red) are represented as tubes on the surface of p62PH (aqua).
Table S1. List of intermolecular NOEs
Tfb1PH K47 HA EKLF L77 HD
Tfb1PH Q49 HA EKLF D76 HA
Tfb1PH Q49 HB EKLF D76 HA
Tfb1PH Q49 HG EKLF D76 HA
Tfb1PH A50 HB EKLF L75 HD
Tfb1PH T51 HG EKLF W73 HH2
Tfb1PH T51 HG EKLF W73 HZ3
Tfb1PH S54 HA EKLF A71 HB
Tfb1PH S54 HB EKLF A71 HB
Tfb1PH S54 HB EKLF A71 HA
Tfb1PH S55 HB EKLF L75 HD
Tfb1PH K57 HE EKLF A71 HA
Tfb1PH K57 HB EKLF A71 HA
Tfb1PH M58 HE EKLF G68 HA
Tfb1PH M59 HE EKLF A69 HA
Tfb1PH M59 HE EKLF D70 HB
Tfb1PH M59 HE EKLF T72 HG
Tfb1PH M59 HE EKLF T72 HB
Tfb1PH M59 HE EKLF W73 HE3
Tfb1PH M59 HE EKLF W73 HZ3
Tfb1PH M59 HE EKLF W73HZ2
Tfb1PH M59 HE EKLF W73 HH2
Tfb1PH M59 HB EKLF W73HH2
Tfb1PH M59 HG EKLF W73 HH2
Tfb1PH M59 HG EKLF W73 HZ2
Tfb1PH M59 HE EKLF L75 HD
Tfb1PH R61 HA EKLF W73 HH2
Tfb1PH R61 HA EKLF W73 HZ3
Tfb1PH M88 HA EKLF W73 HH2
Tfb1PH M88 HA EKLF W73 HZ3
Tfb1PH M88 HB EKLF W73 HH2
Tfb1PH M88 HG EKLF W73 HH2
Tfb1PH M88 HE EKLF A69 HA
Tfb1PH M88 HE EKLF A69 HB
Tfb1PH M88 HE EKLF D70 HB
Tfb1PH M88 HE EKLF A71 HB
Tfb1PH M88 HE EKLF T72 HB
Tfb1PH M88 HE EKLF W73 HE3
Tfb1PH M88 HE EKLF W73 HZ2
Tfb1PH M88 HE EKLF L75 HD
Tfb1PH K101 HE EKLF L75 HG
Tfb1PH K101 HE EKLF L75 HD
Tfb1PH Q105 HA EKLF L79 HD
Tfb1PH Q105 HG EKLF L79 HD
Tfb1PH Q105 HG EKLF L79 HG
Tfb1PH Y111 HA EKLF T80 HG
Tfb1PH K112 HE EKLF L79 HD
Mas et al. www.pnas.org/cgi/doi/10.1073/pnas.1017029108 6 of 7
Table S2. Structural statistics of the Tfb1PH/EKLFTAD2 complex
Restraints used for the structure calculations
Total number of NOE distances restraints 1,686
Short-range (intraresidue) 675




Number of dihedral angle restraints (ϕ, ψ) 116
Structural statistics
rms deviations from idealized geometry
Bonds, Å 0.0027 ± 0.00008
Angles, deg 0.4363 ± 0.0065
Impropers, deg 0.2871 ±0.0098
rms deviations from distance restraints, Å 0.0207 ± 0.0007
rms deviations from dihedral restraints, deg 0.5408 ± 0.0359
Ramachandran statistics, %*
Residues in most favored regions 80.0
Residues in additional allowed regions 17.3
Residues in generously allowed regions 2.6
Residues in disallowed regions 0.1
Coordinate precision†
Atomic pair wise rmsd, Å
Tfb1PH/EKLFTAD2 complex
Backbone atoms (C′, Cα, N) 0.70 ± 0.15
All heavy atoms 1.35 ± 0.19
Tfb1PH alone
Backbone atoms (C′, Cα, N) 0.65 ± 0.15
All heavy atoms 1.32 ± 0.19
EKLFTAD2 alone
Backbone atoms (C′, Cα, N) 0.68 ± 0.22
All heavy atoms 1.35 ± 0.41
The 20 conformers with the lowest energies were selected for statistical
analysis. Because of the absence of medium-range, long-range, and
intermolecular NOEs involving residues 51–58 and 86–90 of EKLFTAD2,
these amino acids were not included in the calculations.
*Based on PROCHECK-NMR analysis.
†Only residues 4–63 and 86–114 of Tfb1PH and residues 70–79 of EKLFTAD2
were used for the rmsd calculations. Residues at the N terminus (1–3), at the
C terminus (113–115), and in the flexible loop (64–85) of Tfb1PH, as well as
residues at the N terminus (59–69) and at the C terminus (80–85) of
EKLFTAD2, were not included in the calculation.
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